Cover Image
市場調查報告書

Interprotein Corporation的產品平台分析

Interprotein Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 226217
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Interprotein Corporation的產品平台分析 Interprotein Corporation - Product Pipeline Review - 2016
出版日期: 2016年03月16日 內容資訊: 英文 33 Pages
簡介

本報告提供Interprotein Corporation的產品開發平台現狀及各開發階段比較分析,提供您藥物簡介,開發平台分析與最新趨勢,以及暫停中的計劃等資訊。

Interprotein Corporation的基本資料

Interprotein Corporation概要

  • 主要資訊
  • 企業資料

Interprotein Corporation:R&D概要

  • 主要的治療範圍

Interprotein Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Interprotein Corporation:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Interprotein Corporation:藥物簡介

  • IPC-003
  • IPZ-010
  • 癌症治療用阻礙VEGF的小分子
  • 過敏治療用阻礙IgE的小分子

Interprotein Corporation:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Interprotein Corporation:最近的開發平台趨勢

Interprotein Corporation:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07984CDB

Summary

Global Markets Direct's, 'Interprotein Corporation - Product Pipeline Review - 2016', provides an overview of the Interprotein Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Interprotein Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Interprotein Corporation
  • The report provides overview of Interprotein Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Interprotein Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Interprotein Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Interprotein Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Interprotein Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interprotein Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Interprotein Corporation Snapshot
  • Interprotein Corporation Overview
  • Key Information
  • Key Facts
  • Interprotein Corporation - Research and Development Overview
  • Key Therapeutic Areas
  • Interprotein Corporation - Pipeline Review
  • Pipeline Products by Stage of Development
  • Pipeline Products - Monotherapy
  • Pipeline Products - Partnered Products
  • Partnered Products/Combination Treatment Modalities
  • Pipeline Products - Out-Licensed Products
  • Out-Licensed Products/Combination Treatment Modalities
  • Interprotein Corporation - Pipeline Products Glance
  • Interprotein Corporation - Early Stage Pipeline Products
  • Preclinical Products/Combination Treatment Modalities
  • Discovery Products/Combination Treatment Modalities
  • Interprotein Corporation - Drug Profiles
  • IPC-003
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecules to Inhibit VEGF for Solid Tumors
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule to Inhibit gp130 for Inflammation and Oncology
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule to Inhibit IgE for Allergies
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecules to Inhibit RUNX1 for Acute Myeloid Leukemia
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit gp130 for Inflammation and Oncology
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Synthetic Peptides to Antagonize KIR for Oncology
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Synthetic Peptides to Antagonize NKG2A for Oncology
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Synthetic Peptides to Inhibit TIM-3 for Oncology
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Interprotein Corporation - Pipeline Analysis
  • Interprotein Corporation - Pipeline Products by Target
  • Interprotein Corporation - Pipeline Products by Route of Administration
  • Interprotein Corporation - Pipeline Products by Molecule Type
  • Interprotein Corporation - Pipeline Products by Mechanism of Action
  • Interprotein Corporation - Recent Pipeline Updates
  • Interprotein Corporation - Dormant Projects
  • Interprotein Corporation - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Interprotein Corporation, Key Information
  • Interprotein Corporation, Key Facts
  • Interprotein Corporation - Pipeline by Indication, 2016
  • Interprotein Corporation - Pipeline by Stage of Development, 2016
  • Interprotein Corporation - Monotherapy Products in Pipeline, 2016
  • Interprotein Corporation - Partnered Products in Pipeline, 2016
  • Interprotein Corporation - Partnered Products/ Combination Treatment Modalities, 2016
  • Interprotein Corporation - Out-Licensed Products in Pipeline, 2016
  • Interprotein Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Interprotein Corporation - Preclinical, 2016
  • Interprotein Corporation - Discovery, 2016
  • Interprotein Corporation - Pipeline by Target, 2016
  • Interprotein Corporation - Pipeline by Route of Administration, 2016
  • Interprotein Corporation - Pipeline by Molecule Type, 2016
  • Interprotein Corporation - Pipeline Products by Mechanism of Action, 2016
  • Interprotein Corporation - Recent Pipeline Updates, 2016
  • Interprotein Corporation - Dormant Developmental Projects,2016
  • Interprotein Corporation, Other Locations

List of Figures

  • Interprotein Corporation - Pipeline by Indication, 2016
  • Interprotein Corporation - Pipeline by Stage of Development, 2016
  • Interprotein Corporation - Monotherapy Products in Pipeline, 2016
  • Interprotein Corporation - Pipeline by Target, 2016
  • Interprotein Corporation - Pipeline by Molecule Type, 2016
  • Interprotein Corporation - Pipeline Products by Mechanism of Action, 2016
Back to Top